Diabetes and beyond: Novo Nordisk plots its future
This article was originally published in Scrip
Executive Summary
A 'super-specialism' in diabetes is clearly working well for Novo Nordisk at present, as the world's largest insulin producer reports total sales growth of 18% in 2012 to DKK78 billion ($14 billion), on strong sales of its diabetes portfolio, in particular Victoza (liraglutide). However, it does not consider this a sustainable long-term plan, if its stated strategic aims are any indication.